Understand the source comparison
Hexarelin Research Review: Peptide Comparison
Hexarelin's position among growth hormone secretagogues and related peptides becomes clearer through direct comparison of receptor binding, clinical endpoints, and documented effects across published trials. Hexarelin GHS-R1a + CD36 25–40 at 1–2 mcg/kg Strong—
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Hexarelin's position among growth hormone secretagogues and related peptides becomes clearer through direct comparison of receptor binding, clinical endpoints, and documented effects across published trials.
- Hexarelin
- GHS-R1a + CD36
- 25–40 at 1–2 mcg/kg
- Strong—RCT-level evidence in heart failure, ischemia models
- ~70 minutes
- Dual receptor activity provides cardioprotection independent of GH release; strongest evidence base for cardiac applications among all GHRPs
- GHRP-6
- GHS-R1a
- 15–30 at 1 mcg/kg
- Minimal—limited to animal models
- ~30 minutes
- Standard GH secretagogue without CD36 activity; appetite stimulation limits some applications
- GHRP-2
- 20–35 at 1 mcg/kg
- Minimal—isolated reports only
- ~40 minutes
- Potent GH release with less appetite stimulation than GHRP-6; no cardioprotective pathway
- Ipamorelin
- 12–25 at 0.5–1 mcg/kg
- None documented
- ~120 minutes
- Selective GHS-R1a agonist with minimal cortisol/prolactin elevation; longer half-life but lower GH peaks
- CJC-1295 (DAC)
- GHRH receptor
- Sustained elevation 10–20 baseline
- 6–8 days
- GHRH analog—different mechanism; sustained low-level GH elevation rather than pulsatile peaks
- MK-677
- GHS-R1a (oral)
- 15–30 sustained
- 24 hours (oral)
- Oral bioavailability advantage; no CD36 activity; long-term desensitization concerns
- The comparison reveals hexarelin's unique dual-pathway activity. While Ipamorelin and GHRP-2 deliver comparable GH secretion, neither activates CD36 receptors—eliminating the cardioprotective and neuroprotective mechanisms that define hexarelin research review literature. MK-677 offers oral bioavailability but lacks the dual receptor profile, while CJC-1295 works through an entirely different receptor system (GHRH rather than ghrelin receptors). For researchers investigating cardiac or neuroprotective applications, hexarelin remains the only peptide in this class with RCT-level evidence in human heart failure patients.
- When sourcing research-grade peptides, receptor specificity and sequence purity determine experimental reproducibility. Our synthesis process at Real Peptides maintains exact amino-acid sequencing through small-batch production—critical for hexarelin given that D-amino acid substitutions at positions 2 and 5 define both receptor binding affinity and enzymatic stability. A single amino acid error eliminates CD36 binding entirely.